Metabolomics analysis of serum and urine in patients with traumatic spinal cord injury

doi:10.12307/2024.426

Abstract

Abstract: BACKGROUND: Traumatic spinal cord injury primarily relies on scale assessment and imaging examinations in clinical practice. However, there are limitations in predicting the prognosis of the injury. Therefore, the use of metabolomics technology for biomarker screening is significant for estimating the extent of damage, injury and recovery, as well as developing new therapies.
OBJECTIVE: To characterize the metabolic features of patients with traumatic spinal cord injury using metabolomics technology and explore potential biomarkers and disrupted metabolic pathways.
METHODS: Serum and urine samples were collected from 20 patients with traumatic spinal cord injury (observation group) and 10 healthy subjects (control group). Metabolites were analyzed and multivariate statistical analysis was then performed for data processing to screen differential metabolites. Metabolic pathway enrichment was performed using MetaboAnalyst software. Logistic regression was applied to construct a biomarker combination model, and its relationship with the American Spinal Injury Association grading was analyzed.
RESULTS AND CONCLUSION: Significant differences in 160 and 73 metabolites were detected in the serum and urine samples of the two groups, respectively. Pathway enrichment analysis showed evident disturbances in lipid metabolism after traumatic spinal cord injury, including sphingolipid, arachidonic acid, α-linolenic acid, and arachidonic acid metabolism, as well as glycerophospholipid and inositol phosphate biosynthesis. The combination of two identified biomarkers, telmisartan and quercetin glycoside, showed a correlation with the American Spinal Injury Association grading in both serum and urine levels. Thus, metabolomics technology provides assistance in further understanding the pathological mechanisms of traumatic spinal cord injury and screening therapeutic targets. The identified metabolic biomarker combination may serve as a reference for assessing the severity of traumatic spinal cord injury.

Key words: traumatic spinal cord injury, metabolomics, biomarker, differential metabolites, ultra-performance liquid chromatography-quadrupole-time of flight mass spectrometry

CLC Number:

Song Jiating, Chen Jianmin, Wang Kewen, Huang Lanying, Xu Senming, Gui Yuchang, Xu Jianwen. Metabolomics analysis of serum and urine in patients with traumatic spinal cord injury[J]. Chinese Journal of Tissue Engineering Research, 2024, 28(32): 5085-5090.

Figures/Tables 8

References

[1] GU Y, CHEN D, ZHOU L, et al. Lysine-specific demethylase 1 inhibition enhances autophagy and attenuates early-stage post-spinal cord injury apoptosis. Cell Death Discov. 2021;7(1):69.
[2] ZHENG Y, MAO YR, YUAN TF, et al. Multimodal treatment for spinal cord injury: a sword of neuroregeneration upon neuromodulation. Neural Regen Res. 2020;15(8):1437-1450.
[3] LAI Z, LIU H, LIU G. Meta-Analysis on the Effects of Electric Acupuncture on Neural Functional Recovery and Related Pathways of Rats after Spinal Cord Injury. Biomed Res Int. 2022;2022:8613384.
[4] KYRITSIS N, TORRES-ESPÍN A, SCHUPP PG, et al. Diagnostic blood RNA profiles for human acute spinal cord injury. J Exp Med. 2021;218(3): e20201795.
[5] BYKOWSKI EA, PETERSSON JN, DUKELOW S, et al. Urinary biomarkers indicative of recovery from spinal cord injury: A pilot study. IBRO Neurosci Rep. 2021;10:178-185.
[6] 杨新乐,王明,杨成伟,等.脊髓损伤的代谢组学研究进展[J].中国康复理论与实践,2018,24(8):904-908.
[7] WANG X, ZHANG L, SUN W, et al. Changes of Metabolites in Acute Ischemic Stroke and Its Subtypes. Front Neurosci. 2021;14:580929.
[8] BANOEI MM, CASAULT C, METWALY SM, et al. Metabolomics and Biomarker Discovery in Traumatic Brain Injury. J Neurotrauma. 2018;35(16):1831-1848.
[9] ZHOU Y, ZHANG X, CHEN R, et al. Serum amino acid metabolic profiles of ankylosing spondylitis by targeted metabolomics analysis. Clin Rheumatol. 2020;39(8):2325-2336.
[10] 梁子超,李智炜,赖铿,等.10折交叉验证用于预测模型泛化能力评价及其R软件实现[J].中国医院统计,2020,27(4):289-292.
[11] RUPP R, BIERING-SØRENSEN F, BURNS SP, et al. International Standards for Neurological Classification of Spinal Cord Injury: Revised 2019. Top Spinal Cord Inj Rehabil. 2021;27(2):1-22.
[12] 康海琼,周红俊,刘根林,等.脊髓损伤神经学分类国际标准检查表2019版最新修订及解读[J].中国康复理论与实践,2019,25(8):983-985.
[13] WANG R, LIU S, LIU T, et al. Mass spectrometry-based serum lipidomics strategy to explore the mechanism of Eleutherococcus senticosus (Rupr. & Maxim.) Maxim. leaves in the treatment of ischemic stroke. Food Funct. 2021;12(10):4519-4534.
[14] KWON BK, STREIJGER F, FALLAH N, et al. Cerebrospinal Fluid Biomarkers To Stratify Injury Severity and Predict Outcome in Human Traumatic Spinal Cord Injury. J Neurotrauma. 2017;34(3):567-580.
[15] FAN B, WEI Z, FENG S. Progression in translational research on spinal cord injury based on microenvironment imbalance. Bone Res. 2022;10(1):35.
[16] PANG Y, LIU X, ZHAO C, et al. LC-MS/MS-based arachidonic acid metabolomics in acute spinal cord injury reveals the upregulation of 5-LOX and COX-2 products. Free Radic Biol Med. 2022;193(Pt 1):363-372.
[17] 胡华辉,黄小龙,全仁夫,等.急性脊髓损伤模型大鼠血清和脊髓的代谢组学研究[J].中国骨伤,2017,30(2):152-158.
[18] LIU Z, KUMAR M, KABRA A. Cucurbitacin B exerts neuroprotection in a murine Alzheimer’s disease model by modulating oxidative stress, inflammation, and neurotransmitter levels. Front Biosci (Landmark Ed). 2022;27(2):71.
[19] JI L, CHEN S, GU G, et al. Discovery of potential biomarkers for human atherosclerotic abdominal aortic aneurysm through untargeted metabolomics and transcriptomics. J Zhejiang Univ Sci B. 2021;22(9):733-745.
[20] DOLCI S, MANNINO L, BOTTANI E, et al. Therapeutic induction of energy metabolism reduces neural tissue damage and increases microglia activation in severe spinal cord injury. Pharmacol Res. 2022;178:106149.
[21] WANG R, SHI L, LIU S, et al. Mass spectrometry-based urinary metabolomics for the investigation on the mechanism of action of Eleutherococcus senticosus (Rupr. & Maxim.) Maxim. leaves against ischemic stroke in rats. J Ethnopharmacol. 2019;241:111969.
[22] FUJIEDA Y, UENO S, OGINO R, et al. Metabolite profiles correlate closely with neurobehavioral function in experimental spinal cord injury in rats. PLoS One. 2012;7(8):e43152.
[23] PENG J, ZENG J, CAI B, et al. Establishment of quantitative severity evaluation model for spinal cord injury by metabolomic fingerprinting. PLoS One. 2014;9(4):e93736.
[24] JONES ZB, REN Y. Sphingolipids in spinal cord injury. Int J Physiol Pathophysiol Pharmacol. 2016;8(2):52-69.
[25] DALKILIC T, FALLAH N, NOONAN VK, et al. Predicting Injury Severity and Neurological Recovery after Acute Cervical Spinal Cord Injury: A Comparison of Cerebrospinal Fluid and Magnetic Resonance Imaging Biomarkers. J Neurotrauma. 2018;35(3):435-445.
[26] HUFFMAN EE, DONG BE, CLARKE HA, et al. Cervical spinal cord injury leads to injury and altered metabolism in the lungs. Brain Commun. 2023; 5(2):fcad091.
[27] MAR FM, DA SILVA TF, MORGADO MM, et al. Myelin Lipids Inhibit Axon Regeneration Following Spinal Cord Injury: a Novel Perspective for Therapy. Mol Neurobiol. 2016;53(2):1052-1064.
[28] PATWARDHAN AM, SCOTLAND PE, AKOPIAN AN, et al. Activation of TRPV1 in the spinal cord by oxidized linoleic acid metabolites contributes to inflammatory hyperalgesia. Proc Natl Acad Sci U S A. 2009;106(44): 18820-18824.
[29] LIM SN, HUANG W, HALL JC, et al. Improved outcome after spinal cord compression injury in mice treated with docosahexaenoic acid. Exp Neurol. 2013;239:13-27.
[30] TANG J, ZENG X, LI H, et al. Repulsive Guidance Molecule-a and Central Nervous System Diseases. Biomed Res Int. 2021;2021:5532116.
[31] MCFADDEN K, MINSHEW NJ. Evidence for dysregulation of axonal growth and guidance in the etiology of ASD. Front Hum Neurosci. 2013;7:671.
[32] FUJITA Y, YAMASHITA T. The roles of RGMa-neogenin signaling in inflammation and angiogenesis. Inflamm Regen. 2017;37:6.
[33] FREUND P, SEIF M, WEISKOPF N, et al. MRI in traumatic spinal cord injury: from clinical assessment to neuroimaging biomarkers. Lancet Neurol. 2019;18(12):1123-1135.
[34] CHAY W, KIRSHBLUM S. Predicting Outcomes After Spinal Cord Injury. Phys Med Rehabil Clin N Am. 2020;31(3):331-343.
[35] MAILLARD MP, ROSSAT J, BRUNNER HR, et al. Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. J Pharmacol Exp Ther. 2000;295(2):649-654.
[36] GROOTHUIS JT, THIJSSEN DH, RONGEN GA, et al. Angiotensin II contributes to the increased baseline leg vascular resistance in spinal cord-injured individuals. J Hypertens. 2010;28(10):2094-2101.
[37] JÄRVE A, TODIRAS M, LIAN X, et al. Distinct roles of angiotensin receptors in autonomic dysreflexia following high-level spinal cord injury in mice. Exp Neurol. 2019;311:173-181.
[38] ASSIS AD, MASCARENHAS FNADP, ARAÚJO FA, et al. Angiotensin-(1-7) receptor Mas antagonist (A779) influenced gliosis and reduced synaptic density in the spinal cord after peripheral axotomy. Peptides. 2020;129: 170329.
[39] KU JM, KIM SR, HONG SH, et al. Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells. Mol Cell Biochem. 2015;409 (1-2):33-43.
[40] MUTALIK SP, GUPTON SL. Glycosylation in Axonal Guidance. Int J Mol Sci. 2021;22(10):5143.
[41] SOLEILHAVOUP C, TRAVAGLIO M, PATRICK K, et al. Nolz1 expression is required in dopaminergic axon guidance and striatal innervation. Nat Commun. 2020;11(1):3111.
[42] Í DALI C, GROESCHEL S, MOLDOVAN M, et al. Intravenous arylsulfatase A in metachromatic leukodystrophy: a phase 1/2 study. Ann Clin Transl Neurol. 2021;8(1):66-80.
[43] CRUZ CD, COELHO A, ANTUNES-LOPES T, et al. Biomarkers of spinal cord injury and ensuing bladder dysfunction. Adv Drug Deliv Rev. 2015;82-83: 153-159.
[44] YANG H, ZHANG P, XIE M, et al. Parallel Metabolomic Profiling of Cerebrospinal Fluid, Plasma, and Spinal Cord to Identify Biomarkers for Spinal Cord Injury. J Mol Neurosci. 2022;72(1):126-135.